SUPPORTING INFORMATION

Conformational Switch to a β-turn in a Staphylococcal Quorum Sensing Signal Peptide Causes a Dramatic Increase in Potency

Joseph K. Vasquez,†,§ Korbin H. J. West,† Tian Yang,†,[⊥] Thomas J. Polaske,† Gabriel Cornilescu,^{‡,∥} Marco Tonelli,[‡] and Helen E. Blackwell^{†,*}

† Department of Chemistry, University of Wisconsin−Madison, Madison, WI 53706 ‡ National Magnetic Resonance Facility at Madison, University of Wisconsin−Madison, Madison, WI 53706

blackwell@chem.wisc.edu

Contents

- Experimental procedures (including **Schemes S1** and **S2**)
- NMR spectra for 3-D solution-phase structures
- *³ J* coupling constants for 3-D solution-phase structures (**Tables S1–S8**)
- Chemical shift assignments for 3-D solution-phase structures (**Tables S9–S16**)
- ROE constraint statistics
- Additional images of structure ensembles (**Figures S1–S9**)
- Validation using MolProbity
- MS and analytical HPLC data for β-turn modifying analogs (**Table S17**)
- Analytical HPLC traces for β-turn modifying analogs
- *S. epidermidis* AgrC-I reporter dose-response activity curves for β-turn modifying analogs
- EC₅₀ and IC₅₀ values for β-turn modifying analogs (**Table S18**)
- NMR spectra for select β-turn modifying analogs
- Chemical shift assignments for select β-turn modifying analogs (**Tables S19–S22**)
- TALOS-N predictions for AIP-I and AIP-I D1AS6A (**Tables S23** and **S24**)
- Discussion of TALOS-N usage with AIPs and AIP analogs
- Comparative chemical shift analysis for select β-turn modifying analogs (**Table S25**)
- Discussion of chemical shift differences for select β-turn modifying analogs
- References

[§]*Current address:* The Dow Chemical Company, 1776 Building, Midland, MI 48640

[⊥]*Current address:* Promega Corporation, 2800 Woods Hollow Rd., Madison, WI 53711

[║]*Current address:* Leidos Biomedical Research, Inc., 8560 Progress Dr., Frederick, MD 21701

Experimental procedures

Chemical reagents, strains, and general methods

All reagents and solvents were purchased from Sigma-Aldrich or Chem-Impex and used as obtained. Water (18 MΩ) was purified using a Barnstead Nanopure from Thermo Scientific. The majority of the peptides used in this study were previously synthesized in our laboratory,¹ and all were purified to homogeneity using established reverse-phase high performance liquid chromatography (RP-HPLC) methods on a Shimadzu instrument composed of SCL-10Avp controller, DGU-14A degasser, FCV-10ALvp solvent mixer, LC-10ATvp pump, CTO-10ASvp column oven with a 5 mL manual injection loop and Kromasil Eternity column (5 um 100 Å C18 packing of 10 mm × 250 mm), SPD-M10Avp diode array detector, and FRC-10A fraction collector. Peptide masses were determined using a Bruker microflex LRF MALDI-TOF mass spectrometer. The *S. epidermidis* GFP agr group-I reporter strain AH3408² was generously donated by Prof. Alexander Horswill (University of Colorado Medical School) and cultured in Tryptic Soy Broth (TSB, from Sigma) supplemented with 10 µg/mL of erythromycin.

Solid-phase peptide synthesis methods

The β-turn modifying peptide analogs of AIP-I D1AS6A and AIP-I D1AV3AS6A (AAA), designed to examine the importance of the β-turn motif, were synthesized according to previously reported protocols (shown in Scheme S1).¹ Approximately 30 mg (0.0147 mmol, 1 eq.) of Fmoc Dawson Dbz AM resin was swelled in DCM for 40 min in a fritted reactor vessel. The resin was washed with DCM (2 mL ×3), DMF (2 mL ×3), and the Fmoc group deprotected with 20% piperidine in DMF (2 mL ×3; 5 min, 5 min, 10 min) while shaking. The deprotected resin was washed with DMF (2 mL ×3). N^a-Fmoc protected amino acid (4 eq.), HATU (4 eq.), and DIPEA (8 eq.) were dissolved in 2 mL DMF, incubated for 5 min, and added to the deprotected resin and shaken (1 h for the first amino acid, 0.5 h for the remaining amino acids). Deprotections and couplings were repeated to couple the remaining amino acids to the resin, with the final amino acid coupling using a Boc-protected amino acid instead of a Fmoc-protected amino acid.

Following the final Boc-protected amino acid coupling, the resin was washed with DMF (2 mL ×3) and DCM (2 mL ×3). Thereafter, 4-nitrophenyl chloroformate (4 eq.) dissolved in 2 mL of DCM was added to the vessel, and the slurry was shaken for 30 min. An additional 2 mL of 4 nitrophenyl chloroformate (4 eq.) in DCM was added to the vessel, and the slurry was shaken for another 30 min. The resin was washed with DCM (2 mL ×3) and treated with 2 mL of 5.5% DIPEA in DMF (10 min ×3). The resin was washed with DMF (2 mL ×3), DCM (2 mL ×3), and Et₂O (2 mL \times 3), dried under N₂, and dried under vacuum. The peptide was cleaved from the resin (while also being deprotected) by treatment with 2 mL of 90/5/2.5/2.5 TFA/DCM/H2O/triisopropylsilane (TIPS) and shaking for 2 h. The solution was filtered, mixed with 40 mL of Et₂O, chilled at -20 $^{\circ}$ C for 1 h to precipitate peptide, and centrifuged using a Beckman-Coulter Allegra 6R with a GH-3.8 rotor at 3500 rpm and 4 °C for 30 min. The supernatant was decanted, the pellet dissolved in 3 mL 50% ACN in H_2O , and lyophilized.

Lyophilized peptide was redissolved in 25% ACN in H2O and purified by RP-HPLC. Fractions containing peptides were identified using MALDI MS and lyophilized. The lyophilized linear peptides were cyclized in 3 mL of cyclization buffer (20% ACN, 80% 6 M guanidinium chloride in 0.1 M Na₂PO₄, pH 6.8) while shaking at 50 °C for 2 h. The cyclized peptide was purified using RP-HPLC; fractions that contained cyclized peptide were identified by MALDI MS. Aliquots of the cyclized peptide fractions were submitted for high-resolution mass measurement and

analytical RP-HPLC to check purity, while the remaining portions of the fractions were lyophilized in pre-massed vials to obtain final isolated yields of approximately 12–23%.

Scheme S1. Solid-phase synthesis of β-turn modifying analogs.

Solid-phase N-methylated peptide synthesis methods

N-methylated analogs of AIP-I D1AS6A and AAA were synthesized and purified following the above peptide synthesis protocol with two exceptions. First, instead of using a standard N^α-Fmoc protected amino acid, an N^α-methyl, N^α-Fmoc protected amino acid was used to load the resin. Second, the coupling time to couple the following N^α-Fmoc protected amino acid was extended to 3 h. Final isolated yields of peptides ranged from approximately 5–16%.

Solid-phase depsipeptide synthesis methods

Depsipeptide analogs of AIP-I D1AS6A and AAA were synthesized by replacing Phe8 with Lphenyllactic acid (PLA) (shown in Scheme S2). Approximately 100 mg (0.1 mmol, 1 eq.) of 2 chlorotrityl resin was swelled in DCM for 10 min in a fritted reactor vessel, and the resin was washed with DCM (2 mL ×3). To load PLA onto the resin, PLA (2 eq.) and DIPEA (4 eq.) were dissolved in 2 mL of DMF, added to the resin, and shaken for 30 min. The resin was washed with DCM (2 mL ×3), and then capped by incubating with 2 mL of a 15% MeOH/5% DIPEA in DCM solution for 10 min while shaking $(x2)$. The resin was washed with DCM (2 mL $x3$) and then with DMF (2 mL ×3). Thereafter, N^α-Fmoc-O-*t*Bu-L-tyrosine (4 eq.), HATU (4 eq.), and DIPEA (8 eq.) were dissolved in 2 mL of DMF, pre-incubated for 5 min, and then added to the PLA-loaded resin vessel and shaken for 16 h. The resin was then washed with DMF (2 mL ×3), then Fmoc deprotected with 2 mL of 20% piperidine in DMF ×3 (5 min, 5 min, 10 min) while shaking. The deprotected resin was washed with DMF (2 mL ×3). The next N^a-Fmoc protected amino acid (4 eq.), HATU (4 eq.), and DIPEA (8 eq.) were dissolved in 2 mL of DMF, preincubated for 5 min, and added to the deprotected resin and shaken for 30 min. Deprotections and couplings were repeated to couple the remaining amino acids to the resin, with the final amino acid coupling using a Boc-protected amino acid instead of a Fmoc-protected amino acid.

Following the final Boc-protected amino acid coupling, the resin was washed with DMF (2 mL \times 3), DCM (2 mL \times 3), MeOH (2 mL \times 3), dried with N₂, and then dried under vacuum. The peptide was cleaved from the resin (while simultaneously deprotecting only the Cys4 thiol from its Mmt protecting group) using 5 mL of 2% TFA/2% TIPS in DCM solution, and shaking for 15 min. The solution was filtered into a 25 mL round-bottom flask, and the resin was treated with another 5 mL of 2% TFA/2% TIPS in DCM solution, shaken for another 15 min, and drained into a 25 mL round bottom flask. A small volume (~0.5 mL) of DMSO was added to the flask, and the DCM was removed under reduced pressure. The remaining approximately 0.5 mL of the peptide dissolved in DMSO was diluted with 25% ACN in water and purified on RP-HPLC. Fractions containing the partially-protected linear depsipeptides were identified by MALDI MS and lyophilized. Yields of partially-protected linear depsipeptides ranged from 1−2%.

The partially-protected linear depsipeptides (1 eq.) were cyclized with PyAOP (1.5 eq.) and DIPEA (2 eq.) in 0.5 mL DMF, stirring for 48 h in a 50 °C water bath. The solvent was removed by rotary evaporation under reduced pressure, and the cyclized, partially-protected depsipeptides were fully deprotected by stirring in 0.5 mL of a 90/5/2.5/2.5 TFA/DCM/H₂O/TIPS solution for 2 h. The solution was removed by rotary evaporation under reduced pressure, leaving a yellow oil. The oil then was diluted with water and purified by RP-HPLC, and fractions that contained cyclized depsipeptide were identified with MALDI MS. Aliquots of the cyclized depsipeptide fractions were submitted for high-resolution mass measurement and analytical RP-HPLC to check purity, while the remaining portions of the fractions were lyophilized in premassed vials to obtain isolated yields of approximately 21−58% (relative to linear starting material).

Scheme S2. Solid-phase synthesis of depsipeptides.

Fluorescent AgrC-I reporter assay protocol

Peptides were evaluated for agr activity using the *S. epidermidis* GFP agr group-I reporter strain AH3408.² A culture of AH3408 was grown overnight at 37 °C with shaking at 200 rpm, after which it was diluted 1:50 in fresh TSB medium. Peptide stocks (1 mM) were serially diluted in DMSO, and 2 uL aliquots were transferred to wells in triplicate within a black 96-well microtiter plate. For antagonism assays, 198 µL of the diluted AH3408 culture were added to each well. For agonism assays, 2 µL of a 2.5 µM AAA stock solution (final concentration in plate: 25 nM) were added to each well to block agr activity, and subsequently 196 uL of diluted AH3408 culture were transferred into each well. Separate from the test wells, each plate also included two controls: a vehicle control (wells containing only 2 or 4 µL DMSO with dilute AH3408 culture for agonism or antagonism assays, respectively), and a media control (wells containing TSB medium only). Plates were incubated with shaking (200 rpm) at 37 °C for 24 h. Fluorescence (excitation at 500 nm, emission at 540 nm) and the $OD₆₀₀$ of each well were measured using a BioTek Synergy 2 plate reader. Measurements were processed by subtracting background fluorescence (TSB medium), correcting to $OD₆₀₀$, and then normalizing using the respective DMSO control for the agonism and antagonism assays. Non-linear regression curves were fitted to the data sets with GraphPad Prism software (version 7) by using variable slope (fourparameter) dose-response analysis to obtain potency, efficacy, and statistical information about the activity profiles of the tested peptides.

NMR methods and spectral analyses

To obtain solution structures of key peptides, NMR experiments (1-D proton, 2-D TOCSY, and 2- D ROESY) and subsequent analyses of the spectral data were carried out using our previously reported methods.³ In brief, peptides were dissolved in $H_2O:D_2O$ (95:5), except for AIP-I which was dissolved in 12.5% CD₃CN in H₂O and t-AIP-I which was dissolved in 30% CD₃CN in H₂O at pH 5. Final concentrations of each peptide were at least 700 µM. These NMR spectra were obtained on a Bruker Avance-III 750 MHz spectrometer equipped with a TXI cryoprobe using standard pulse sequences at ambient temperature. Solvent suppression of the water peak was achieved using excitation sculpting, and chemical shifts in the spectra were referenced to residual H₂O at 4.79 ppm or CD_3CN at 1.94 ppm.

All spectra were analyzed using MestReNova 10 NMR processing software, with important ³J couplings and chemical shifts provided in Tables S1−S16. Resonance assignments for each peptide, calculations of interproton distances from ROESY cross peak volumes, and the threedimensional structure calculations and refinements were completed according to established methods.⁴⁻⁶ ROE constraint specifics are provided below.

An average structure for each peptide was determined from an ensemble of the 20 lowestenergy structures from a set of 100 total structures obtained by torsion angle simulated annealing in Xplor-NIH.⁷⁻¹³ During refinement, an initial constraint allowance of ±20% of each calculated ROE was used to determine initial structures with a soft potential. Final refinement was done with a constraint allowance of $\pm 10\%$ of each calculated ROE plus an additional 0.5 Å using a hard potential for the final structures. The average structure was used as a comparative tool, from which a representative structure with a small RMS difference from the average structure was selected from the low-energy ensemble. These representative structures are shown in the main text (Figures 3−8). Additional images are provided in Figures S1–S9. Visual analysis, structure comparisons with alignment fitting, and presentation of the peptide structures were performed with PyMOL.¹⁴ For consistent RMS fitting in PyMOL, degenerate hydrogens

were numbered for consistent relative coordinates. Final representative structures were validated using MolProbity.¹⁵⁻¹⁶

Additional NMR experiments (1-D proton, 2-D TOCSY, and 2-D ¹H-¹³C HSQC) were performed to compare the chemical shifts of select peptides. Peptides were dissolved in D_2O at pH 5, with the exception of AIP-I which was dissolved in 12.5% CD_3CN in D_2O at pH 5. Final concentrations of each peptide were at least 700 µM. Spectra were obtained on a Varian 800 MHz spectrometer with a HCN cryoprobe using standard pulse sequences at ambient temperature. Chemical shifts within the spectra were referenced to a DMSO internal standard at 2.71 ppm (1 H) or 39.39 ppm (13 C). The chemical shift data for AIP-I and AIP-I D1AS6A were entered into the TALOS-N program in attempt to predict torsion angles (see additional discussion below). 17-18

NMR spectra for 3-D solution-phase structures

One-dimensional proton, 2-D TOCSY, and 2-D ROESY NMR experiments were performed for each peptide as described in the experimental procedures above. Selected parameters for each experiment are included in each spectrum. For the 2-D experiments, blue indicates negative peak intensity and green indicates positive peak intensity.

• AIP-I¹H NMR spectrum (700 µM dissolved in 12.5% CD₃CN in H₂O, pH ~6.5)

• *AIP-I 1 H-1 H TOCSY spectrum*

• *AIP-I 1 H−¹ H ROESY spectrum*

• *t-AIP-I* ¹H NMR spectrum (1.5 mM dissolved in 30% CD₃CN in H₂O, pH ~5 with HCl)

• *t-AIP-I ¹ H−¹ H TOCSY spectrum*

• AIP-I V3A ¹H spectrum (1 mM dissolved in 95% H₂O with 5% D₂O, pH ~6.5)

• *AIP-I V3A 1 H−¹ H TOCSY spectrum*

• *AIP-I V3A 1 H−¹ H ROESY spectrum*

• AIP-I D1A ¹H NMR spectrum (1 mM dissolved in 95% H₂O with 5% D₂O, pH ~6.5)

• *AIP-I D1A 1 H−¹ H TOCSY spectrum*

• *AIP-I D1A 1 H−¹ H ROESY spectrum*

S-18

• AIP-I D1AS6A¹H NMR spectrum (1 mM dissolved in 95% H₂O with 5% D₂O, pH ~6.5)

• *AIP-I D1AS6A 1 H−¹ H TOCSY spectrum*

• *AIP-I D1AS6A 1 H−¹ H ROESY spectrum*

• *AIP-I D1AV3AS6A (AAA) ¹ H NMR spectrum (1.5 mM dissolved in 95% H2O with 5% D2O, pH ~6.5)*

S-22

• *AAA 1 H−¹ H TOCSY spectrum*

• *AAA 1 H−¹ H ROESY spectrum*

• AIP-II¹H NMR spectrum (1 mM dissolved in 95% H₂O with 5% D₂O, pH ~6.5)

• *AIP-II 1 H−1 H TOCSY spectrum (20 ms spin lock)*

• *AIP-II 1 H−¹ H TOCSY spectrum (120 ms spin lock)*

• *AIP-II 1 H−1 H ROESY spectrum*

• AIP-III¹H NMR spectrum (1 mM dissolved in 95% H₂O with 5% D₂O, pH ~6.5)

• *AIP-III ¹ H−¹ H TOCSY spectrum (20 ms spin lock)*

• *AIP-III ¹ H−¹ H TOCSY spectrum (120 ms spin lock)*

• *AIP-III ¹ H−¹ H ROESY spectrum*

3J **coupling constants for 3-D solution-phase structures**

3 J coupling constants are listed below (if resolved from spectra).

Residue	$H\alpha$ -HN	$H\alpha$ –H β_1		$H\alpha - H\beta_2$ $H\beta_1 - H\beta_2$ $H\alpha - H\beta$		Нβ−Нγ1	$H\beta$ – $H\gamma$ 2
Ser ₂	7.1						
Val3	8.3				8.2	7.2	7.0
Cys4	7.4	11.2	4.7	14.4			
Ala ₅	7.0				7.5		
Ser ₆	8.5	$4.8*$	$4.5*$	11.6			
Tyr7	6.8	3.8	9.7	14.9			
Phe8	9.3	4.3	10.7	14.9			

Table S1: Important 3 *J* coupling constants of AIP-I in Hz

** indicates stereochemistry ambiguous, not defined*

Table S2: Important 3 *J* coupling constants of t-AIP-I in Hz

Residue				$H\alpha$ -HN $H\alpha$ -Hβ ₁ Hα-Hβ ₂ Hβ ₁ -Hβ ₂ Hα-Hβ Hβ-Hγ1 Hβ-Hγ2		
Cys1	7.7	10.6	4.5	13.8		
Ala ₂	6.7				7.3	
Ser ₃	8.3	$4.8*$	$6.5*$	11.7		
Tyr4	6.5	5.7	9.5	14.8		
Phe ₅	9.6	4.5	11.0	14.8		

** indicates stereochemistry ambiguous, not defined*

Table S3: Important ³J coupling constants of AIP-I V3A in Hz

Residue	$H\alpha$ –HN			Hα-Hβ ₁ Hα-Hβ ₂ Hβ ₁ -Hβ ₂ Hα-Hβ		$Hβ$ −Hγ1	$H\beta$ -H _y 2
Ser ₂	6.6						
Ala3	6.8				7.8		
Cys4	7.6	10.6	4.5	14.0			
Ala ₅	6.3				7.7		
Ser ₆	8.4	$5.1*$	$6.7*$	11.6			
Tyr7	6.4	6.2	9.6	14.8			
Phe8	9.4	4.3	11.0	14.9			

** indicates stereochemistry ambiguous, not defined*

Residue	$H\alpha$ -HN	$H\alpha - H\beta_1$		$H\alpha - H\beta_2$ $H\beta_1 - H\beta_2$ $H\alpha - H\beta$		$H\beta$ –H γ 1	$H\beta$ – $H\gamma$ 2
Ser ₂	6.9	$5.3*$	$6.9*$	11.6			
Val ₃	8.1				7.9	7.1	7.1
Cys4	7.4	10.8	4.5	14.0			
Ala5	7.0				7.4		
Ser ₆	8.5	$5.2*$	$6.8*$	11.4			
Tyr7	6.7	5.9	9.6	14.9			
Phe8	9.4	4.4	11.0	14.9			

Table S4: Important ³J coupling constants of AIP-I D1A in Hz

** indicates stereochemistry ambiguous, not defined*

Table S5: Important ³J coupling constants of AIP-I D1AS6A in Hz

Residue	$H\alpha$ -HN			$H\alpha$ -H β_1 H α -H β_2 H β_1 -H β_2 H α -H β		Нβ−Нγ1	$H\beta$ –Hy2
Ser ₂	7.0	$5.3*$	$6.5*$	11.6			
Val ₃	8.2				8.3	7.2	7.2
Cys4	7.3	10.9	4.6	14.2			
Ala ₅	7.3				7.5		
Ala ₆	8.2				7.6		
Tyr7	7.4	6.3	10.0	14.4			
Phe8	9.4	4.0	11.1	15.0			

** indicates stereochemistry ambiguous, not defined*

Residue				$H\alpha$ -HN Hα-Hβ ₁ Hα-Hβ ₂ Hβ ₁ -Hβ ₂ Hα-Hβ Hβ-Hγ1		$H\beta$ – $H\gamma$ 2
Ser ₂	6.5					
Ala3	6.4				7.2	
C _{VS} 4	7.4	10.4	4.5	14.1		
Ala ₅	7.0				7.3	
Ala ₆	8.4				7.3	
Tyr7	7.2	6.2	9.6	14.4		
Phe8	9.3	4.2	10.9	14.9		

Table S6: Important ³J coupling constants of AIP-I D1AV3AS6S (AAA) in Hz

** indicates stereochemistry ambiguous, not defined*

Residue	$H\alpha$ -HN	$H\alpha$ –H β_1	$H\alpha - H\beta_2$	$H\beta_1$ – $H\beta_2$	$H\alpha$ -H β	H_{γ} -H δ 1	H_{γ} -H δ 2
Ala ₂	5.7				7.4		
Ser ₃	6.6	$6.1*$	$5.5*$	11.4			
Lys4	7.0						
Tyr ₅	7.3	$7.8*$	$8.3*$	13.9			
Asn ₆	8.2	$7.3*$	$7.2*$	16.0			
Pro7							
Cys8	7.2	11.1	4.7	14.2			
Ser9	8.0	$6.3*$	$5.6*$	12.0			
Asn10	8.1	$7.8*$	$6.4*$	15.6			
Tyr11	7.4	6.1	9.1	14.1			
Leu12	9.3					7.0	7.0

Table S7: Important ³J coupling constants of AIP-II in Hz

** indicates stereochemistry ambiguous, not defined*

** indicates stereochemistry ambiguous, not defined*

Chemical shift assignment for 3-D solution-phase structures

Table S9: Assignments for AIP-I

Table S10: Assignments for t-AIP-I

Table S11: Assignments for AIP-I V3A

HN (ppm)	$H\alpha$ (ppm)	$H\beta$ (ppm)	Others (ppm)
	4.06	1.46	
8.61	4.47	3.78, 3.78	
8.25	4.04	1.97	Hy 0.81, 0.84
8.55	4.41	2.91, 3.32	
8.47	4.24	1.29	
8.32	4.02	3.68, 3.77	
7.96	4.24	2.42, 2.67	$H\delta$ 6.83; Hε 6.70
8.44	4.83	2.83, 3.38	$H\delta$ 7.15; Hε 7.30; Hζ 7.24

Table S12: Assignments for AIP-I D1A

Table S13: Assignments for AIP-I D1AS6A

Residue HN (ppm)		$H\alpha$ (ppm) $H\beta$ (ppm)		Others (ppm)		
Ala1		4.05	1.46			
Ser ₂	8.60	4.47	3.76, 3.79			
Val ₃	8.24	4.04	1.96	HY 0.81, 0.84		
C _{VS} 4	8.53	4.41	2.88, 3.32			
Ala ₅	8.47	4.22	1.28			
Ala6	8.36	3.97	1.24			
Tyr7	7.69	4.22	2.58, 2.69	$H\delta$ 6.82; H _{ϵ} 6.69		
Phe8	8.43	4.80	2.83, 3.42	$H\delta$ 7.20; Hε 7.32; Hζ 7.24		

Table S14: Assignments for AIP-I D1AV3AS6A (AAA)

Residue	HN (ppm)	$H\alpha$ (ppm)	$H\beta$ (ppm)	Others (ppm)
Asn1		4.34	2.94, 3.01	$H\delta$ 7.05, 7.50
Ala ₂	8.73	4.42	1.41	
Ser ₃	8.38	4.41	3.83, 3.87	
Lys4	8.34	4.26	1.65, 1.70	$Hγ$ 1.28; H δ 1.60, 1.66; Hε 2.96
Tyr ₅	8.20	4.54	2.93, 2.96	$H\delta$ 7.10; $H\epsilon$ 6.81
Asn6	8.25	4.93	2.58, 2.77	$H\delta$ 6.86, 7.55
Pro7		4.30	1.96, 2.23	$Hγ$ 1.94, 1.98; H δ 3.49, 3.63
C _{VS}	8.37	4.43	2.93, 3.39	
Ser ₉	8.56	4.46	3.77, 3.79	
Asn ₁₀	8.69	4.39	2.85, 2.89	$H\delta$ 6.93, 7.63
Tyr11	8.15	4.52	3.12, 3.17	$H\delta$ 7.15; $H\epsilon$ 6.87
Leu12	8.24	4.54	1.64, 1.74	Hy 1.29; H _{δ} 0.81, 0.88

Table S15: Assignments for AIP-II

Table S16: Assignments for AIP-III

ROE constraint statistics

 $AIP-T$

```
total NOEs in noe-sq.tbl residue 1 to residue 8: 66
intra\_residual (j-i = 0): 46
                   20sequential (j-i = 1):
medium range (j-i = 2): 0
medium range (j-i = 3):
                   \overline{0}medium range (j-i = 4):
                   \bigcirclong range (j-i \ge 5):
                    \bigcapresidue 1 has 2 NOEs
residue 2 has 5 NOEs
residue 3 has 9 NOEs
residue 4 has 7 NOEs
residue 5 has 6 NOEs
residue 6 has 8 NOEs
residue 7 has 19 NOEs
residue 8 has 10 NOEs
```
$t - \lambda T P - T$

total NOEs in noe-sq.tbl residue 0 to residue 5: 63 intra residual $(j-i = 0)$: 33 sequential $(j-i = 1)$: 25 medium range $(j-i = 2)$: 2 medium range $(j-i = 3)$: 1 medium range $(j-i = 4)$: 2 long range $(j-i \ge 5)$: $\overline{0}$ residue 0 has 1 NOEs residue 1 has 9 NOEs residue 2 has 10 NOEs residue 3 has 12 NOEs residue 4 has 21 NOEs residue 5 has 10 NOEs

AIP-I V3A

== total NOEs in noe-sq.tbl residue 1 to residue 8: 78 == intra residual $(j-i = 0): 41$ sequential $(j-i = 1):$ 34 medium range $(j-i = 2)$: 1 medium range $(j-i = 3)$: 0 medium range $(j-i = 4)$: 2 long range $(j-i \ge 5)$: 0 residue 1 has 7 NOEs residue 2 has 9 NOEs residue 3 has 5 NOEs residue 4 has 9 NOEs residue 5 has 6 NOEs residue 6 has 10 NOEs residue 7 has 20 NOEs residue 8 has 12 NOEs

AIP-I D1A

== total NOEs in noe-sq.tbl residue 1 to residue 8: 88 == intra residual $(j-i = 0): 39$ sequential $(j-i = 1):$ 39 medium range $(j-i = 2)$: 6 medium range $(j-i = 3)$: 0 medium range $(j-i = 4)$: 4 long range $(j-i \geq 5)$: 0 residue 1 has 6 NOEs residue 2 has 9 NOEs residue 3 has 13 NOEs residue 4 has 12 NOEs residue 5 has 6 NOEs residue 6 has 15 NOEs residue 7 has 18 NOEs residue 8 has 9 NOEs

AIP-I D1AS6A

== total NOEs in noe-sq.tbl residue 1 to residue 8: 74 == intra residual $(j-i = 0): 37$ sequential $(j-i = 1):$ 30 medium range $(j-i = 2)$: 2 medium range $(j-i = 3)$: 1 medium range $(j-i = 4)$: 4 long range $(j-i \ge 5)$: 0 residue 1 has 2 NOEs residue 2 has 7 NOEs residue 3 has 12 NOEs residue 4 has 11 NOEs residue 5 has 6 NOEs residue 6 has 8 NOEs residue 7 has 20 NOEs residue 8 has 8 NOEs

AIP-I D1AV3AS6A (AAA)

== total NOEs in noe-sq.tbl residue 1 to residue 8: 72 == intra residual $(j-i = 0): 32$ sequential $(j-i = 1):$ 31 medium range $(j-i = 2)$: 1 medium range $(j-i = 3)$: 1 medium range $(j-i = 4)$: 7 long range $(j-i \geq 5)$: 0 residue 1 has 3 NOEs residue 2 has 6 NOEs residue 3 has 5 NOEs residue 4 has 15 NOEs residue 5 has 7 NOEs residue 6 has 7 NOEs residue 7 has 20 NOEs residue 8 has 9 NOEs

AIP-II

== total NOEs in noe-sq.tbl residue 1 to residue 12: 158 == intra residual $(j-i = 0): 82$ sequential $(j-i = 1):$ 56 medium range $(j-i = 2)$: 14 medium range $(j-i = 3)$: 5 medium range $(j-i = 4)$: 0 long range $(j-i \geq 5)$: 1 residue 1 has 11 NOEs residue 2 has 6 NOEs residue 3 has 16 NOEs residue 4 has 16 NOEs residue 5 has 19 NOEs residue 6 has 16 NOEs residue 7 has 13 NOEs residue 8 has 8 NOEs residue 9 has 9 NOEs residue 10 has 11 NOEs residue 11 has 20 NOEs residue 12 has 13 NOEs

AIP-III

== total NOEs in noe-sq.tbl residue 1 to residue 12: 137 == intra residual $(j-i = 0): 75$ sequential $(j-i = 1):$ 52 medium range $(j-i = 2)$: 8 medium range $(j-i = 3)$: 0 medium range $(j-i = 4)$: 2 long range $(j-i \geq 5)$: 0 residue 1 has 11 NOEs residue 2 has 8 NOEs residue 3 has 6 NOEs residue 4 has 12 NOEs residue 5 has 17 NOEs residue 6 has 13 NOEs residue 7 has 13 NOEs residue 8 has 11 NOEs residue 9 has 6 NOEs residue 10 has 8 NOEs residue 11 has 21 NOEs residue 12 has 11 NOEs

Additional images of structure ensembles

Figure S1: Heavy atom ensemble of the 20 lowest-energy structures for AIP-I. Backbone RMSD from average = 0.4 Å, heavy atom RMSD from average = 1.2 Å.

Figure S2: Heavy atom ensemble of the 20 lowest-energy structures for t-AIP-I. Backbone RMSD from average = 0.1 Å, heavy atom RMSD from average = 0.5 Å.

Figure S3: Heavy atom ensemble of the 20 lowest-energy structures for AIP-I V3A. Backbone RMSD from average = 0.3 Å, heavy atom RMSD from average = 1.0 Å.

Figure S4: Heavy atom ensemble of the 20 lowest-energy structures for AIP-I D1A. Backbone RMSD from average = 0.1 Å, heavy atom RMSD from average = 0.7 Å.

Figure S5: Heavy atom ensemble of the 20 lowest-energy structures for AIP-I D1AS6A. Backbone RMSD from average = 0.1 Å, heavy atom RMSD from average = 0.5 Å.

Figure S6: Heavy atom ensemble of the 20 lowest-energy structures for AIP-I D1AV3AS6A (AAA). Backbone RMSD from average = 0.2 Å, heavy atom RMSD from average = 0.6 Å.

Figure S7: Heavy atom ensemble of the 20 lowest-energy structures for AIP-II. Backbone RMSD from average = 0.4 Å, heavy atom RMSD from average = 1.1 Å.

Figure S8: Heavy atom ensemble of the 20 lowest-energy structures for AIP-III. Backbone RMSD from average = 0.3 Å, heavy atom RMSD from average = 0.9 Å.

Figure S9: Overlay of the macrocycles from AAA, AIP-II, and AIP-III. The tails are removed for clarity. All-atom RMS difference of AIP-II to AAA = 1.9 Å, and all-atom RMS difference of AIP-III to AAA = 1.2 Å.

Validation using MolProbity

• *Analysis of AIP-I representative structure*

PROBITY

Viewing AIP-I-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Viewing AIP-I-multi.table

Analysis of AIP-II representative structure \bullet

5/8/2019

Viewing AIP-II-multi.table - MolProbity

U

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of AIP-III representative structure \bullet

5/8/2019

Viewing AIP-III-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of t-AIP-I representative structure \bullet

5/8/2019

Viewing t-AIP-I-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of AIP-I D1A representative structure \bullet

5/8/2019

Viewing D1A-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of AIP-I V3A representative structure \bullet

5/8/2019

Viewing V3A-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of AIP-I D1AS6A representative structure \bullet

5/8/2019

Viewing AA-multi.table - MolProbity

Viewing AA-multi.table

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

Analysis of AIP-I AAA representative structure \bullet

5/8/2019

Viewing AAA-multi.table - MolProbity

Duke Biochemistry Duke University School of Medicine

When finished, you should close this window

Hint: Use File | Save As... to save a copy of this page.

In the two column results, the left column gives the raw count, right column gives the percentage.

* 100th percentile is the best among structures of comparable resolution; 0th percentile is the worst. For clashscore the comparative set of structures was selected in 2004, for MolProbity score in 2006.

MolProbity score combines the clashscore, rotamer, and Ramachandran evaluations into a single score, normalized to be on the same scale as X-ray resolution.

MS and analytical HPLC data for β-turn modifying analogs

Table S17: MS spectral data, HPLC retention times, and purity data for the β-turn modifying analogs. The m/z of each peptide is given as $[M+H]$ ⁺.

Analytical HPLC traces for β-turn modifying analogs

AIP-I D1AS6dA

AIP-I D1AS6G

AIP-I D1AS6A [N-MeF8]

20
Minutes

 $\frac{1}{22}$

 $\frac{1}{24}$

 $\frac{1}{26}$

AAA [N-MeF8]

AAA [F8PLA]

S. epidermidis **AgrC-I reporter dose-response activity curves for β-turn modifying analogs**

Error bars indicate standard deviation (SD). Three biological replicates were used to generate each curve. Curves for the parent agonist (AIP-I D1AS6A) and antagonist (AAA) are also provided. See assay protocol in the experimental procedures section above for details of method.

Agonists

S-60

EC50 and IC50 values for β-turn modifying analogs

Table S18: Cell-based reporter activities in AgrC-I of agonist AIP-I D1AS6A, antagonist AAA, and the $β$ -turn modifying peptide analogs.

CI = 95% confidence interval.

NMR spectra for select β-turn modifying analogs

Two-dimensional ¹H-¹³C HSQC NMR experiments were performed for each peptide as described in the experimental procedures above, along with 1-D proton and 2-D TOCSY NMR experiments for select peptides. Selected parameters for each experiment are included in each spectrum. For the 2-D experiments, blue indicates negative peak intensity and red indicates positive peak intensity.

• AIP-I¹H-¹³C HSQC NMR spectrum (700 μ M dissolved in 12.5% CD₃CN in D₂O, pH ~5)

S-62

• AIP-I D1AS6A¹H NMR spectrum (1.43 mM dissolved in D₂O, pH \sim 5)

• *AIP-I D1AS6A ¹ H-13C HSQC NMR spectrum*

• AIP-I D1AS6dA¹H NMR spectrum (1.43 mM dissolved in D₂O, pH ~5)

• *AIP-I D1AS6dA ¹ H-1 H TOCSY NMR spectrum*

• *AIP-I D1AS6dA ¹ H-13C HSQC NMR spectrum*

• AIP-I D1AS6A [N-MeF8] ¹H NMR spectrum (1.43 mM dissolved in D₂O, pH \sim 5)

• *AIP-I D1AS6A [N-MeF8] ¹ H-1 H TOCSY NMR spectrum*

• *AIP-I D1AS6A [N-MeF8] ¹ H-13C HSQC NMR spectrum*

Residue	$H\alpha$ (ppm)	c_{α} (ppm)	$H\beta$ (ppm)	$C\beta$ (ppm)	Others (ppm)
Asp1	4.32	50.73	3.06, 3.11	35.37	
Ser ₂	4.56	56.20	3.87	61.61	
Val ₃	4.13	55.26	2.08	30.87	Hy 0.92, 0.93 and Cy 18.92, 18.23
C _{VS} 4	4.50	52.67	3.01, 3.39	29.56	
Ala5	4.40	50.11	1.39	17.09	
Ser ₆	4.15	59.94	3.77, 3.86	59.91	
Tyr7	4.30	57.16	2.52, 2.76	36.00	
Phe ₈	4.90	60.81	2.93, 3.48	36.81	

Table S19: Assignments for AIP-I

Table S20: Assignments for AIP-I D1AS6A

Residue	$H\alpha$ (ppm)	c_{α} (ppm)	$H\beta$ (ppm)	$C\beta$ (ppm)	Others (ppm)
Ala1	4.15	49.63	1.55	17.21	
Ser ₂	4.56	56.00	3.85, 3.87	61.71	
Val ₃	4.15	60.02	2.05	30.98	Hy 0.90, 0.93 and Cy 18.91, 18.32
Cys4	4.56	52.44	2.84, 3.42	30.05	
Ala5	4.54	48.50	1.34	17.04	
dAla6	4.18	50.93	1.19	15.74	
Tyr7	4.35	56.32	2.32, 2.75	35.56	
Phe8	4.91	61.20	2.90, 3.59	37.24	

Table S21: Assignments for AIP-I D1AS6dA

Table S22: Assignments for AIP-I D1AS6A [N-MeF8]

Residue	$H\alpha$ (ppm)	c_{α} (ppm)	$H\beta$ (ppm)	$C\beta$ (ppm)	Others (ppm)
Ala1	4.14	49.63	1.55	17.22	
Ser ₂	4.57	56.03	3.86, 3.88	61.71	
Val ₃	4.15	60.08	2.08	30.95	Hy 0.93, 0.95 and Cy 18.92, 18.34
Cys4	4.35	53.67	3.12, 3.38	29.24	
Ala ₅	4.28	51.01	1.39	16.11	
Ala6	4.21	51.55	1.26	17.13	
Tyr7	4.23	73.91	3.03, 3.35	33.84	
N-MePhe8	4.96	51.22	2.83, 2.91	37.02	N-Me H 2.83, C 40.12
TALOS-N predictions for AIP-I and AIP-I D1AS6A

Residue	Predicted			Observed*		
	Phi	Psi	CLASS	Phi	Psi	Ramachandran
Asp1	none	none	none	none	45.393	N/A
Ser ₂	-103.427 ± 26.247	101.222 ± 63.095	warn	-153.616	146.409	MATCH
Val3	-103.571 ± 14.362	126.446 ± 5.802	strong	-126.956	128.62	MATCH
C _{VS} 4	-104.668 ± 14.482	130.147 ± 12.928	strong	-125.294	121.087	MATCH
Ala5	-104.113 ± 26.363	135.859 ± 24.183	generous	-135.013	61.471	MISMATCH
Ser ₆	-68.757 ± 15.126	-17.975 ± 17.111	warn	-174.485	-97.422	MISMATCH
Tyr7	-90.578 ± 11.683	0.962 ± 11.899	strong	-68.035	-37.567	MATCH
Phe ₈	none	none	none	-135.013	none	N/A

Table S23: Torsion angle analysis for AIP-I

*As determined from the solution-phase NMR structure in this study.

Residue	Predicted			Observed [*]		
	Phi	Psi	CLASS	Phi	Psi	Ramachandran
Ala1	none	none	none	none	63.436	N/A
Ser ₂	-90.000 ± 13.261	129.065 ± 12.271	strong	-149.893	157.675	MATCH
Val3	-100.836 ± 14.319	122.150 ± 8.839	strong	-117.633	105.724	MATCH
Cys4	$-111.628 + 9.710$	134.821 ± 10.895	strong	-144.247	136.439	MATCH
Ala ₅	-102.063 ± 28.363	133.140 ± 22.407	warn	-133.073	141.684	MATCH
Ala6	-87.544 ± 22.952	128.997 ± 32.590	warn	62.737	-88.195	MISMATCH
Tyr7	-104.505 ± 28.071	139.797 ± 14.313	warn	-125.077	15.963	MISMATCH
Phe ₈	none	none	none	-133.073	none	N/A

Table S24: Torsion angle analysis for AIP-I D1AS6A

*As determined from the solution-phase NMR structure in this study.

Discussion of TALOS-N usage with AIPs and AIP analogs

The TALOS-N program (https://spin.niddk.nih.gov/bax/software/TALOS-N/) is an artificial neural network based system for the prediction of protein backbone φ/ψ torsion angles, sidechain χ1 torsion angles, and secondary structure using NMR chemical shift assignments. Along with angle predictions for specific residues, TALOS-N assigns a level of confidence to each prediction (indicated in the "CLASS" columns of Tables S23 and S24 above). 17-18 Predictions classified as "strong" indicate that the 25 best database matches to the residue are well-clustered on the Ramachandran map. If instead only the top 10 best database matches are well-clustered, the prediction is classified as "generous." All other cases are considered ambiguous and are designated as "warn." However, even with the "warn" status, the φ/ψ angle predictions can still be useful if clustered.

Although some of the TALOS-N predictions of the AIP-I and AIP-I D1AS6A residue torsion angles are "strong," just as many are classified as "generous" or "warn," and these do not always match the regions of the Ramachandran map in which these angles were determined experimentally to reside (via their solution-phase NMR structures; Tables S23 and S24). As these peptides look different from the natural proteins the TALOS-N database utilizes, especially in regard to the constrained thiolactone macrocycle, the lack of consistent, high quality predictions is perhaps not surprising. That said, the TALOS-N predictions appear consistent within the exocyclic tail regions (residues 1-3 in the peptides tested herein), most likely because being outside the macrocycle allows these residues to adopt conformations commonly found in proteins within the database that TALOS-N queries.

Comparative chemical shift analysis for select β-turn modifying analogs

Table S25: Calculated NMR chemical shift differences between AIP-I D1AS6A and either AIP-I D1AS6dA or AIP-I D1AS6A [N-MeF8]. Positive values indicate the shift of the analog's atom is further downfield than the corresponding shift in AIP-I D1AS6A, while negative values indicate the shift is further upfield. A standard method was used to determine the threshold for which chemical shift differences were deemed significant, and these shifts are indicated in yellow (see calculations below).¹⁹ Briefly, the mean and standard deviation of the chemical shift difference magnitudes were calculated for each nucleus, and the significance threshold was set at any shift with a magnitude greater than two standard deviations above the mean.

Calculation of the mean for proton chemical shift differences:

$$
\mu_{\rm H} = \frac{\sum^{N} \left| \delta_{\rm H[AIP\text{-}I\;D1AS6A]} - \delta_{\rm H[analogs]} \right|}{N} = 0.09 \text{ ppm}
$$

Standard deviation calculation for proton chemical shift differences:

$$
\sigma_{\rm H} = \sqrt{\frac{\sum^N (\delta_{\rm H[analog]} - \mu_{\rm H})^2}{N - 1}} = 0.14 \text{ ppm}
$$

Determination of the cutoff value for significant proton shifts differences: Proton Cutoff $\geq \mu_H + 2\sigma_H = 0.37$ ppm

Calculation of the mean for carbon chemical shift differences:

$$
\mu_{\rm C} = \frac{\sum^{N} \left| \delta_{\rm C[AIP\text{-}I\,D1ASGA]} - \delta_{\rm C[analogs]} \right|}{N} = 1.20 \text{ ppm}
$$

Standard deviation calculation for carbon chemical shift differences:

$$
\sigma_{\rm C} = \sqrt{\frac{\sum^N (\delta_{\rm C[analog]} - \mu_{\rm C})^2}{N - 1}} = 3.34 \text{ ppm}
$$

Determination of the cutoff value for significant carbon shifts differences: Carbon Cutoff $\geq \mu_C + 2\sigma_C = 7.88$ ppm

Discussion of chemical shift differences for select β-turn modifying analogs

When comparing the 1 H and 13 C chemical shifts for analogous residues between AIP-I D1AS6A and either AIP-I D1AS6dA or AIP-I D1AS6A [N-MeF8], the ¹H and ¹³C shifts of the exocyclic residues were nearly identical. The chemical shift differences were within 0.03 ppm for ¹H chemical shifts and 0.06 ppm for ¹³C chemical shifts (see Table S25 above).

For the endocyclic residues, the differences were slightly larger than those in the exocyclic tails for similar residues (<0.25 or <1 ppm for most ¹H or ¹³C shifts, respectively; see Table S25), unless a large difference in conformation was suspected. The most significant differences are commented on here. The first macrocyclic residue, Cys4, exhibits little variation in chemical shifts in most of the peptides, but there is a noticeable 0.2 ppm change in the Hα shift and a 1 ppm difference in the Cα shift of AIP-I D1AS6A [N-MeF8]. With Ala5, all three peptides exhibit small changes in Hα, Cα, and Cβ shifts relative to each other. For the sixth residue, either L-Ala or D-Ala fills this position, and the ¹H and ¹³C shifts all differ between the peptides. Interestingly, AIP-I D1AS6A and AIP-I D1AS6A [N-MeF8] share the same amino acid at this residue (L-Ala) and at the flanking positions, yet there are ¹H and ¹³C shift differences at Ala6 between the two peptides, suggestive of a conformational difference between these two peptides and that the β-turn structure could be perturbed in AIP-I D1AS6A [N-MeF8]. Of all the changes in chemical shifts between the three peptides, the largest deviation occurs in Tyr7. While the shifts of Tyr7 in AIP-I D1AS6A and AIP-I D1AS6dA are very close, and almost indistinguishable in some cases (differences of <0.05, <0.9, <0.4, <0.05, and <0.05 ppm for H α , C α , H β 1, H β 2, and C β respectively), there are large shift differences for AIP-I D1AS6A [N-MeF8]. Most notable are those that surpass two standard deviations above the average shift displacement, namely the Cα with a shift difference of >15 ppm and Hβ2 with a shift difference of >0.5 ppm. These large changes in chemical shifts for AIP-I D1AS6A [N-MeF8], alongside a smaller but still noticeable Cβ shift of 1.7 ppm, suggests a perturbation in the local conformation around this residue, presumably as a result of the *N*-methylation of Phe8. Lastly, while the final residues' shifts are fairly consistent between AIP-I D1AS6A and AIP-I D1AS6dA, there are significant shift differences in Hβ and Cα of AIP-I D1AS6A [N-MeF8] (0.6 and 10 ppm, respectively), again, presumably due to the *N*-methylation of Phe8 in this analog.

References

- 1. Yang, T.; Tal-Gan, Y.; Paharik, A. E.; Horswill, A. R.; Blackwell, H. E. Structure–Function Analyses of a *Staphylococcus epidermidis* Autoinducing Peptide Reveals Motifs Critical for AgrC-type Receptor Modulation. *ACS Chem. Biol.* **2016,** *11*, 1982-1991.
- 2. Olson, M. E.; Todd, D. A.; Schaeffer, C. R.; Paharik, A. E.; Van Dyke, M. J.; Butner, H.; Dunman, P. M.; Rohde, H.; Cech, N. B.; Fey, P. D.; Horswill, A. R. *Staphylococcus epidermidis* agr quorum-sensing system: signal identification, cross talk, and importance in colonization. *J. Bacteriol.* **2014**, *196*, 3482-3493.
- 3. Vasquez, J. K.; Tal-Gan, Y.; Cornilescu, G.; Tyler, K. A.; Blackwell, H. E. Simplified AIP-II Peptidomimetics are Potent Inhibitors of *Staphylococcus aureus* AgrC Quorum Sensing Receptors. *ChemBioChem* **2017,** *18*, 413-423.
- 4. Cavanagh, J.; Fairbrother, W. J.; Palmer, A. G.; Skelton, N. J. *Protein NMR Spectroscopy: Principles and Practice*. Academic Press, Elsevier Science: 1995.
- 5. Wüthrich, K. *NMR of Proteins and Nucleic Acids*. John Wiley and Sons: New York: 1986.
- 6. Evans, J. N. S. *Biomolecular NMR Spectroscopy*. Oxford University Press: New York, 1995.
- 7. Nilges, M.; Clore, G. M.; Gronenborn, A. M. Determination of three-dimensional structures of proteins from interproton distance data by hybrid distance geometry-dynamical simulated annealing calculations. *FEBS Lett.* **1988,** *229*, 317-324.
- 8. Schwieters, C. D.; Clore, G. M. Internal Coordinates for Molecular Dynamics and Minimization in Structure Determination and Refinement. *J. Magn. Reson.* **2001,** *152*, 288- 302.
- 9. Clore, G. M.; Kuszewski, J. χ1 Rotamer Populations and Angles of Mobile Surface Side Chains Are Accurately Predicted by a Torsion Angle Database Potential of Mean Force. *J. Am. Chem. Soc.* **2002,** *124*, 2866-2867.
- 10. Schwieters, C. D.; Kuszewski, J. J.; Tjandra, N.; Clore, G. M. The Xplor-NIH NMR Molecular Structure Determination Package. *J. Magn. Reson.* **2003,** *160*, 66-74.
- 11. Schwieters, C. D.; Kuszewski, J. J.; Clore, G. M. Using Xplor-NIH for NMR molecular structure determination. *Prog. Nucl. Magn. Reson. Spectrosc.* **2006,** *48*, 47-62.
- 12. Schwieters, C. D.; Clore, G. M. A Pseudopotential for Improving the Packing of Ellipsoidal Protein Structures Determined from NMR Data. *J. Phys. Chem. B* **2008,** *112*, 6070-6073.
- 13. Schwieters, C. D.; Bermejo, G. A.; Clore, G. M. Xplor-NIH for molecular structure determination from NMR and other data sources. *Protein Sci.* **2018,** *27*, 26-40.
- 14. The PyMOL Molecular Graphics System, Version 1.7, Schrödinger, LLC.: 2015.
- 15. Davis, I. W.; Leaver-Fay, A.; Chen, V. B.; Block, J. N.; Kapral, G. J.; Wang, X.; Murray, L. W.; Arendall, W. B., 3rd; Snoeyink, J.; Richardson, J. S.; Richardson, D. C. MolProbity: allatom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res.* **2007,** *35*, W375-W383.
- 16. Chen, V. B.; Arendall, W. B., 3rd; Headd, J. J.; Keedy, D. A.; Immormino, R. M.; Kapral, G. J.; Murray, L. W.; Richardson, J. S.; Richardson, D. C. MolProbity: all-atom structure validation for macromolecular crystallography. *Acta Crystallogr., Sect. D: Struct. Biol.* **2010,** *66*, 12-21.
- 17. Shen, Y.; Bax, A. Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. *J. Biomol. NMR* **2013,** *56*, 227-241.
- 18. Shen, Y.; Bax, A. Protein structural information derived from NMR chemical shift with the neural network program TALOS-N. *Methods Mol. Biol.* **2015,** *1260*, 17-32.
- 19. Williamson, M. P., Using chemical shift perturbation to characterise ligand binding. *Prog. Nucl. Magn. Reson. Spectrosc.* **2013**, *73*, 1-16.